|
|
||||||||
1 Max Planck Institute for Physiological and Clinical Research, W. G. Kerckhoff Institute, 61231 Bad Nauheim, Germany; and 2 Institute of Veterinary Physiology, University of Zurich, 8057 Zurich, Switzerland
| |
ABSTRACT |
|---|
|
|
|---|
Amylin is secreted
with insulin from the pancreas during and after food intake. One of the
most potent actions of amylin in vivo is its anorectic effect, which is
directly mediated by the area postrema (AP), a circumventricular organ
lacking a functional blood-brain barrier. As we recently demonstrated,
amylin also stimulates water intake most likely via its excitatory
action on subfornical organ (SFO) neurons. Neurons investigated under equal conditions in an in vitro slice preparation of the rat AP were
15-fold more sensitive to amylin than SFO neurons. Amylin (10
11-10
8 M) excited 48% of 94 AP
neurons tested; the remaining cells were insensitive. The average
threshold concentration of the excitatory response was
10
10 M and, thus, close to physiological plasma
concentrations. Coapplication of the amylin receptor antagonist AC-187
reduced amylin's excitatory effect. Amylin-mediated activation of AP
neurons and antagonistic action of AC-187 were confirmed in vivo by
c-fos studies. Peripherally applied amylin stimulated cGMP
formation in AP and SFO neurons, as shown in immunohistochemical
studies. This response was independent of nitric oxide (NO) formation
in the AP, while coapplication of the NO synthase inhibitors
N-monomethyl-L-arginine (100 mg/kg) and
nitro-L-arginine methyl ester (50 mg/kg) blocked cGMP
formation in the SFO. In contrast to the SFO, where NO-dependent cGMP
formation seems to represent a general inhibitory transduction pathway, cGMP acts as an excitatory second messenger in the AP, since the membrane-permeable analog 8-bromo-cGMP stimulated 65% of all neurons tested (n = 17), including seven of nine
amylin-sensitive neurons (77%). The results indicate that the
anorectic effect of circulating amylin is based on its excitatory
action on AP neurons, with cGMP acting as a second messenger.
food intake; water intake; electrophysiology; nitric oxide; subfornical organ
| |
INTRODUCTION |
|---|
|
|
|---|
AMYLIN IS A
37-AMINO ACID peptide that is secreted with
insulin from pancreatic
-cells in response to nutrient stimuli
(5, 36, 50). The most potent actions of circulating amylin
affect the gastrointestinal system and ingestive behavior. As a partner hormone to insulin, amylin controls nutrient intake as well as nutrient
influx to the blood by an inhibition of food intake, gastric emptying,
and glucagon secretion (3, 13, 21, 26, 51, 52). At least
the first two of these effects are mediated by the area postrema (AP)
(9, 23), a hindbrain circumventricular organ (CVO) that
lacks a functional blood-brain barrier (14) and contains a
high density of amylin receptors (45).
We recently suggested that amylin might also be implicated in the stimulation of food-associated drinking, since subcutaneously applied amylin increased water intake in euhydrated rats to the same degree as ANG II in equimolar doses (34). It is conceivable that the subfornical organ (SFO) mediates the amylin-induced water intake, since amylin exerts an excitatory effect on ANG II-sensitive SFO neurons (34, 35), which is generally accepted to account for the ANG II-mediated induction of thirst.
To extend our investigations on the cellular mechanisms involved in the centrally mediated actions of amylin, we sought to examine the effect of amylin on the electrical activity of AP neurons in an in vitro slice preparation. With the use of AC-187 as a selective amylin receptor antagonist, the involved receptor type was characterized pharmacologically in electrophysiological experiments. These studies were supplemented by immunohistological experiments aiming at detecting c-Fos as a marker for neuronal activation subsequent to peripheral amylin administration.
Using immunohistochemical detection of cGMP formation after peripheral amylin application, we also addressed the possible role of intracellular cGMP signaling in amylin's excitatory effect on AP neurons. Generation of cGMP as a second messenger signal may involve different signaling pathways. Membrane-bound guanylyl cyclase was shown to be coupled to the receptor for the atrial natriuretic factor. Soluble guanylyl cyclase serves as a target for nitric oxide (NO) formed after activation of the constitutive neuronal isoform of NO synthase (nNOS) (12, 28). In contrast to the SFO, where a large quantity of nNOS was detected immunohistochemically and by NADPH-diaphorase staining, the AP contains little nNOS (17, 38). In previous electrophysiological and immunohistochemical studies, NO-dependent cGMP formation in the SFO has been found to reduce neuronal activity (32).
Therefore, we also paid special attention to the NO dependency of amylin's effect on cGMP formation in AP neurons. To discriminate NO-dependent from NO-independent effects, the NOS inhibitors N-monomethyl-L-arginine (L-NMMA) and nitro-L-arginine methyl ester (L-NAME) were used. Additionally, a double-labeling procedure was designed to detect cGMP-positive neurons immunohistochemically and NO-producing cells by NADPH-diaphorase staining. Finally, the membrane-permeating analog 8-bromo-cGMP (8-BrcGMP) was used in electrophysiological experiments to mimic the effect of intracellular cGMP formation on the activity of AP neurons.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
For all experiments, male adult Wistar rats (170-230 g) were used. They had ad libitum access to standard laboratory rat chow and water and were maintained on an artificial 12:12-h dark-light cycle (lights on at 7 AM).
Electrophysiological Studies
Slice preparation and signal recording. The extracellular recording method was described previously for the recording of SFO neurons (35). Rats were decapitated at 10 AM, and their brains were quickly removed and superfused with ice-cold artificial cerebrospinal fluid (aCSF) composed of (in mM) 124 NaCl, 5 KCl, 1.2 NaH2PO4, 1.3 MgSO4, 1.2 CaCl2, 26 NaHCO3, and 10 glucose, equilibrated with 95% O2-5% CO2 (pH 7.4, 290 mosmol/kg). A slice of the medulla oblongata was isolated by two coronal sections rostral and caudal to the AP. The slice was trimmed to contain only the AP and immediately adjacent parts of the nucleus of the solitary tract (NTS). The AP could easily be identified by its V-shaped appearance.
After 2 h of preincubation in aCSF at 35°C, the slice was transferred to the recording chamber and fixed to the bottom of the chamber with a small metal weight. The gold-plated brass recording chamber contained 0.7 ml of aCSF, which was constantly perfused at a rate of 1.6 ml/min after it was prewarmed to chamber temperature, which was maintained at 37.0°C by a feedback-controlled thermoelectric element. Glass-coated platinum-iridium electrodes were used to make extracellular recordings from AP neurons. Action potential recordings were amplified and displayed on a storage oscilloscope (Gould), passed through a window discriminator (World Precision Instruments), and analyzed with custom software (spike2, Cambridge Electronic Design) on a personal computer.Drug application.
Rat amylin (Amylin Pharmaceuticals, San Diego, CA) and 8-BrcGMP (Sigma,
Deisenhofen, Germany) were added to the aCSF shortly before
application. Both drugs were stored in frozen aliquots (
24°C) and
kept on ice until use during an experiment. As a standard stimulus, 10 ml of aCSF containing amylin (10
9-10
8
M) or 8-BrcGMP (10
3 M) were superfused per stimulus.
After a stable recording from a single neuron had been established, its
responsiveness was tested by switching to a perfusion solution
containing the drug.
Dose-response relationship and antagonist studies.
A dose-response relationship for the effect of amylin on AP neurons was
established by superfusing 10
11-10
8 M
amylin. To investigate whether the amylin-induced effect depends on
amylin receptors, the amylin receptor antagonist AC-187
(10
7-10
6 M; gift from Amylin
Pharmaceuticals) was applied with amylin.
Data analysis. The average discharge rate of each neuron was evaluated for 60 s before the stimulus from the continuously recorded ratemeter counts. This value (referred to as "control") was used to normalize changes in firing rate, expressed as percent change from control. If the average change in discharge rate during the entire response time was larger than ±20%, the neuron was considered sensitive to the applied substance. Furthermore, to avoid possible false-positive responses, the effects of all agents had to be reversible to be included in this study. The effect parameters of the electrophysiological responses are expressed as means ± SE. Recording sites in the horizontal subregions of the AP were designated 1 (caudal), 2 (middle), and 3 (rostral). Differences between proportions of sensitive neurons in these subregions were evaluated using Fisher's exact test. Differences were considered significant at P < 0.05.
Immunohistological Studies
Detection of c-fos expression. All treatments were conducted during the first 4 h of the light phase. For the immunohistochemical detection of c-fos expression, amylin was injected at 5 µg/kg ip (n = 3). This dose of amylin has been adapted from previous studies demonstrating a potent amylin-mediated inhibition of feeding via AP neurons (20, 23). The amylin receptor antagonist AC-187 (500 µg/kg ip) was injected 10 min before amylin administration (n = 3); control animals received sterile saline (n = 3). At 90 min after amylin or control administration, animals were deeply anesthetized with pentobarbital sodium (100 mg/kg ip) and transcardially perfused with ice-cold sodium phosphate buffer (PB, 0.1 M, pH 7.4) and then with 4% paraformaldehyde in PB. Sections of the medulla oblongata containing the AP were postfixed and cryoprotected at 4°C in 4% paraformaldehyde (1 h) and 10% sucrose in PB (2 h), respectively.
Cryosections (20 µm) were cut on a cryostat and thawed on poly-L-lysine-covered slides, which were air-dried at room temperature. After rehydration in phosphate-buffered saline (PBS) containing 0.1% Triton X-100 (PBS-T, pH 7.4), sections were incubated in 0.3% PBS-T for 48 h at 4°C using a 1:1,000 dilution of a rabbit polyclonal antiserum directed against c-Fos (Ab5, Calbiochem-Novabiochem, Bad Soden, Germany). After they were washed in 0.1% PBS-T, sections were incubated for 75 min at room temperature with Cy3-conjugated goat anti-rabbit immunoglobulin (Dianova, Hamburg, Germany). Sections were rinsed in PBS and mounted in Citifluor [1:1 (vol/vol) PBS-glycerol; Citifluor Products, Kent, UK]. Digitalized photographs were taken on a fluorescence microscope (Zeiss Axioskop). For quantification of the c-Fos response, c-Fos-immunoreactive (IR) cells were counted from 12-29 representative slices per animal. The cell counts from all animals of the same treatment group were pooled and are expressed as means ± SE. Statistical differences between the treatment groups were analyzed by Kruskal-Wallis one-way analysis of variance on ranks followed by Dunn's multiple comparison procedures. Differences were considered significant at P < 0.05.Detection of cGMP formation.
In the immunohistochemical studies for the detection of cGMP formation,
animals were pretreated with 3-isobutyl-1-methylxanthine (IBMX, 10 mg/kg ip; Sigma) to prevent degradation of cGMP. At 15 min after IBMX
administration, amylin was subcutaneously injected at 784 µg/kg (1 ml/kg of 2 × 10
4 M, n = 3). The NOS
inhibitors L-NMMA (100 mg/kg; Alexis, Grünberg, Germany) and L-NAME (50 mg/kg; Alexis) were
injected with IBMX (n = 2) to analyze the NO dependency
of cGMP formation. Control animals received IBMX or IBMX together with
the respective NOS inhibitor (n = 2 per treatment
group). Anesthesia and fixation were started 25 min after amylin
administration; procedures were the same as those described for the
c-fos studies.
NADPH-diaphorase staining. For the NADPH-diaphorase staining, tissue sections from amylin-treated animals were processed for cGMP detection, allowing a direct comparison of cGMP staining and NOS activity in identical sections. Sections were washed in PB (pH 7.4) and incubated in the dark for 2 h at 37°C in 0.1 M PB (pH 8.0) containing 55 µM NADPH, 0.12 mM nitroblue tetrazolium, and 0.3% Triton X-100 (all from Sigma). Photographs were taken using Kodak Ektachrome 400 film. The specificity of the NADPH-diaphorase staining for NOS had been confirmed by a previous study using the same protocol (32).
| |
RESULTS |
|---|
|
|
|---|
Electrophysiological Study
In total, 97 single-unit recordings were obtained from 64 preparations of the AP, including all studies on the effects of amylin and 8-BrcGMP. The spontaneous discharge rate of the recorded neurons ranged from 0.1 to 14 Hz. Stimulations were performed for ~6 min using
10
8 M amylin and
10
3 M 8-BrcGMP.
Superfusion with amylin (10
9-10
8 M)
excited 48% of all neurons tested with this drug (n = 94). The remaining neurons (52%) were insensitive. All amylin-induced
responses were reversible; inhibitory effects were not observed. Figure
1 shows a continuous ratemeter recording
of a spontaneously active AP neuron that was dose dependently excited
by amylin. The average threshold concentration for the excitatory
responses was 10
10 M (Fig. 1, inset). In the
top traces of Fig. 1, representative segments of the
original spike recording taken at the end of each amylin application
(traces 1 and 2) and during basal activity (trace 3) are illustrated. Compared with our previous
studies on SFO neurons (34), AP neurons were 15-fold more
sensitive to amylin applied under equal recording conditions, because
quantitatively comparable responses were obtained at 15-fold lower
amylin concentrations. The average effect parameters of all
amylin-mediated responses induced by 10
8 M amylin on AP
neurons are summarized in Table 1.
|
|
In 59 of the 94 recordings with amylin as a stimulus, the recording
site was topographically identified. Amylin-sensitive neurons
were not distributed evenly throughout the AP. As illustrated in Fig.
2, the percentage of amylin-sensitive
neurons was significantly higher in the caudal and middle subregions of
the AP than in the medial subregion of the rostral part. Although the
level of significance was not reached, amylin-sensitive neurons also
appeared to be more numerous in the rostrolateral than in the
rostromedial subregion of the AP.
|
To confirm that the amylin-induced excitation was driven by specific
amylin receptors, stimulations were performed in the presence of the
amylin receptor antagonist AC-187
(10
7-10
6 M), which effectively blocks
the action of amylin on SFO neurons (34, 35). When
superfused alone, AC-187 caused inhibitory effects between
23% and
53% on four of six neurons tested. Although amylin-induced
excitations were not completely abolished by coapplication of AC-187,
the agonistic action of amylin was strongly reduced in all cases
compared with the stimulation of identical neurons without AC-187
(
50 ± 7%, n = 6). Figure
3 shows a recording in which AC-187 alone
exerted a moderate inhibitory response but strongly reduced the
amylin-mediated excitation. After washout of the antagonist,
responsiveness to amylin almost completely recovered (Fig. 3).
|
To disclose a potential role of cGMP formation for the neuronal
activity in the AP, the membrane-permeating analog 8-BrcGMP (10
3 M) was superfused to mimic the effect of
intracellular cGMP formation in AP neurons. 8-BrcGMP exerted reversible
excitatory effects (Fig. 4) on 65% of
all neurons tested (n = 17). Data quantifying the
effect parameters are presented in Table 1. Fourteen of 17 neurons
tested with 8-BrcGMP could additionally be tested with amylin. Amylin
excited seven of nine neurons excited by 8-BrcGMP (Table
2). Figure
5 displays a recording of an AP
neuron that was activated by 8-BrcGMP and amylin.
|
|
|
Immunohistological Studies
Expression of c-fos.
The electrophysiological results, demonstrating an excitatory effect of
amylin on AP neurons in vitro, could be confirmed in vivo by detection
of c-fos expression in AP neurons after intraperitoneal injection of amylin. Although c-Fos-IR cells were almost absent in the
AP under control conditions, a significant increase in c-Fos-IR neurons
was detected in the AP after amylin treatment (0.7 ± 0.1 and
44.7 ± 2.1 counts/section for control and amylin, respectively,
P < 0.001; Fig. 6).
Analogous to the regional distribution of amylin-sensitive neurons, the
density of positively labeled cells was higher in the caudal and middle
parts of the AP, whereas in the rostral part, c-Fos-IR neurons were
mainly restricted to the lateral regions (not shown). Amylin also
stimulated a strong c-fos expression in the NTS (Fig. 6).
|
cGMP formation.
A peripheral subcutaneous injection of amylin (784 µg/kg) stimulated
a strong cGMP formation in cell bodies and fibers of AP neurons,
whereas no cGMP-labeled cells were detected under control conditions
(Fig. 7, top). The average
number of cGMP-IR cells in the amylin-treated group was 40.8 ± 3.1 counts/section and was thus significantly higher than in controls
(P < 0.001). In contrast to the amylin-stimulated
c-fos expression, positively labeled cell bodies were absent
in the NTS region and were exclusively restricted to the AP. However,
cGMP-IR fibers apparently projecting from the AP to the NTS were
identified. The regional distribution of cGMP-IR neurons throughout the
AP matched the distributions of the amylin-sensitive as well as the
c-Fos-IR neurons, because cGMP-IR cells were preferably located in the
caudal, middle, and rostrolateral parts of AP (not shown).
|
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The present electrophysiological studies provide the first
evidence that amylin potently activates neurons in the AP, which is
considered an essential mediator of the anorectic effect as well as the
slowing of gastric emptying induced by this pancreatic hormone. The
excitatory effect of amylin was dose dependent and reversible and
occurred at a threshold concentration of 10
10 M, which is
close to physiological plasma concentrations of amylin, which are
between 5 and 100 pM (5). The sensitivity of AP neurons to
amylin was 15-fold higher than that for neurons located in the SFO
(34), another CVO that is equally accessible to
blood-borne peptides. These different sensitivities as well as
different couplings to intracellular second messenger systems (see
below) suggest the involvement of different receptor subtypes in the
SFO and the AP. However, if different receptor subtypes were involved, the amylin receptor antagonist AC-187 would bind to both receptor subtypes, since it blocked the amylin-induced excitatory effects in
both structures (34, 35).
On the basis of these results, we propose that circulating amylin
reduces food intake via an excitatory action on AP neurons located
outside the blood-brain barrier. This hypothesis is strongly substantiated by in vivo studies demonstrating that the anorectic effect of peripherally administered amylin is blunted in AP-lesioned rats (23). The role of the AP as a physiological target
for circulating amylin is furthermore supported by the topographical correspondence of neuronal amylin responsiveness determined
electrophysiologically in vitro and by demonstration of
c-fos activation after amylin application in vivo. The
distribution of excitable neurons across the AP found in vitro was
similar to that of c-Fos-IR cell nuclei determined
immunohistochemically after systemic application of amylin at 5 µg/kg
ip. The doses of amylin and its receptor antagonist applied in vivo in
the present study to demonstrate their opposing actions on
c-fos expression were the same as those used previously for
the pharmacological characterization of amylin as an anorectic hormone
(24) and, consequently, were not chosen with the intention to estimate the threshold of the amylin action in vivo. The injection of amylin at 5 µg/kg ip represents an ~28-fold higher dose than the
ED50 for the anorectic effect of amylin reported recently (33) in a study in which amylin was infused intravenously
(2.9 pmol · kg
1 · min
1 for
15 min). The threshold dose of continuously infused amylin was
estimated to be 1-3
pmol · kg
1 · min
1, which
increased the plasma levels of amylin by 9-24 pM (2). These plasma levels of amylin were only slightly above the increase in
plasma amylin after a large meal given to rats after 18 h of food
deprivation (8 pM).
It was a further objective of the present work to analyze the involvement of intracellular cGMP formation in the effect of amylin on neuronal activity. Special attention was paid to a possible mediation by the messenger molecule NO, which is known to be released after activation of the enzyme NOS (12, 28). As an activator of the soluble guanylyl cyclase, NO may induce cGMP formation and thus alter neuronal activity. In the SFO, different excitatory stimuli (glutamate and ANG II) triggered the release of NO from NOS-containing neurons with the subsequent formation of NO-dependent cGMP, and NO and cGMP exclusively showed inhibitory effects (32). These observations resulted in the hypothesis that excitatory agents in general might exert this action as a protective negative-feedback mechanism against excessive neuronal activation (41). In line with this hypothesis, it was found that calcitonin, a dipsogenic peptide exerting exclusively excitatory actions on SFO neurons (43), induced an NO-dependent cGMP formation in part of these neurons (40).
The present study further confirms the compatibility of this hypothesis with the excitatory action of amylin on SFO neurons by showing that it induced cGMP production in SFO neurons that could be blocked by pretreatment with NOS inhibitors. Thus the notion may be generalized that NO-dependent cGMP formation is stimulated in the SFO by excitatory peptide hormones. Consequently, in the SFO, cGMP can be excluded as the direct second messenger of amylin, as well as of ANG II and calcitonin, since the consistently inhibitory actions of NO and cGMP, respectively, contrast with the primary excitatory actions of each of these peptides.
The exclusively excitatory action of amylin on SFO neurons is most likely mediated by cAMP, which has been shown to account for various other effects of amylin (6, 30, 31, 47). Stimulation of cGMP in the SFO by amylin in an NO-dependent fashion would fit with the idea of a secondary protective role of cGMP as a mediator limiting excessive neuronal excitation in this particular CVO.
Interestingly, in many brain tissues including the SFO, it appears that two different subsets of neurons, which are tightly codistributed, form part of the NO-cGMP signaling cascade. One subset represents nNOS-containing and NO-producing neurons; the other cells contain soluble guanylyl cyclase and are thus able to produce cGMP in response to NO release (7). The present results obtained by double staining of amylin-induced cGMP and NADPH-diaphorase activity underline the physiological relevance of this spatial relationship. In the SFO, NOS and cGMP were never colocalized in the same neuron, but NO-producing neurons were located close to those cells that produced cGMP in response to amylin, suggesting a coupling of nNOS activation and the subsequent release of NO with the formation of cGMP in the surrounding cells. This observation is consistent with the codistribution of NO-producing and NO-reactive SFO neurons detected by in vitro studies using the NO donor sodium nitroprusside to induce cGMP formation (32). In these and other studies (17), the identity of cells positively labeled for NADPH-diaphorase activity with nNOS-containing neurons was confirmed immunohistochemically to validate the use of NAPDH-diaphorase activity as a marker of nNOS.
The present study shows that amylin-induced cGMP in the AP differs fundamentally from that in the SFO, both with regard to its mechanism of formation and its action. In fact, the immunohistological data of this study show that the amylin-induced cGMP formation in the AP is completely independent of the NOS system, since treatment with the NOS inhibitors L-NMMA and L-NAME did not affect the formation of this second messenger. This observation is in line with the low abundance of nNOS in the AP (1, 17).
A blockade of NO release by NOS inhibitors, as well as a reversal of this effect by the substrate L-arginine, has been used in electrophysiological approaches to characterize a potential influence of NO and subsequent cGMP formation on neuronal activity. In line with our histological observations, the discharge rate of AP neurons remained unaltered in response to inhibition of NOS (48), while neuronal activity could be influenced in the SFO (32) and in other sites where the NOS system has been proposed to modulate neuronal function such as the NTS (48) and the spinal cord (42).
Our histochemical evidence of a very low incidence of nNOS in the AP is consistent with other studies reporting a low abundance of NOS in this structure (17). The distribution of the few NADPH-diaphorase-positive neurons in the AP was completely unrelated to that of the cGMP-IR neurons. Especially, the latter observation suggests that amylin-stimulated cGMP production of AP neurons should be mediated by a guanylyl cyclase that is not identical to the soluble guanylyl cyclase that is activated by NO. Although the structural basis of amylin receptors has recently been revealed by the discovery of receptor activity-modifying proteins (4, 25, 27), a receptor-intrinsic guanylyl cyclase activity, as is known for the atrial natriuretic factor receptor (11) and present in the AP (15, 29), has not been described for the amylin receptor.
In our electrophysiological experiments, 8-BrcGMP consistently excited AP neurons. This contrasts with the exclusively inhibitory effects of this cGMP analog on SFO neurons. Most of those AP neurons that were excited by 8-BrcGMP were also activated by amylin. Together with the immunohistochemical evidence, these studies suggest that cGMP mediates the excitatory effect of amylin in the AP. Mechanistically, cGMP may directly increase neuronal activity and/or affect other second messenger systems such as cAMP by activating cGMP-dependent ion channels or altering the activity of cytoplasmic phosphodiesterases (12, 44).
The distribution of amylin-sensitive AP neurons determined by electrophysiological recordings corresponded closely to that found after in vivo stimulation with amylin for cGMP and c-Fos immunoreactivity in the caudal, middle, and anterior regions of the AP. In addition, however, c-Fos-IR neurons were also found in the NTS, a structure within the blood-brain barrier. Because of the strong axonal interconnections of the AP with the NTS (16, 46, 49), NTS neurons are most likely activated secondarily in vivo after amylin injection. Our most recent observation demonstrating that amylin-induced c-fos expression in the NTS is suppressed in AP-lesioned rats (unpublished) supports this suggestion.
Other brain sites that are part of an ascending pathway conveying information from the brain stem to the forebrain include the lateral parabrachial nucleus, the central nucleus of the amygdala, and the bed nucleus of the stria terminalis. As reported earlier (39), peripheral application of amylin induces a strong c-fos expression in these sites that is absent in AP-lesioned animals. Although not included in our present report, we could confirm these results. This indicates that activation in these brain sites is driven by synaptic interaction and not by a direct action of amylin on neurons located in these nuclei. Thus it appears that neurons of the AP are the primary receptive targets for circulating amylin, while the NTS, the lateral parabrachial nucleus, the central nucleus of the amygdala, and the bed nucleus of the stria terminalis may function as important relay and/or integrative centers. This is also suggested by our most recent data indicating that amylin infusion directly into the AP effectively suppresses food intake (unpublished observations). Together with our present finding of a direct excitatory effect of amylin on AP neurons, this observation corroborates earlier studies showing that amylin, in contrast to the satiety effects of bombesin and cholecystokinin, inhibits food intake independently of afferent vagal transmission (10, 18-20, 22, 37).
In summary, our present results provide functional and histological evidence that the anorectic hormone amylin, which is released in response to food intake and is known to suppress feeding via an AP-dependent mechanism, potently activates AP neurons. We propose that the excitatory effect of amylin is the neurophysiological correlate for its anorectic action. We further hypothesize that the amylin-induced activation of AP neurons is driven by direct (NO-independent) intracellular formation of cGMP, since the membrane-permeating analog 8-BrcGMP excited amylin-sensitive neurons in the AP.
Perspectives
To further elucidate the neuronal mechanisms that are involved in the amylin-mediated suppression of feeding, future studies should address whether manipulations of intracellular cGMP signaling in the AP (guanylate cyclase inhibitors/stimulators and 8-BrcGMP) affect food intake. Similarly, it would be of interest whether blockade of guanylate cyclase in vitro inhibits the excitatory effect of amylin on AP neurons. Together with immunohistological evidence for the colocalization of c-Fos and cGMP after amylin injection, such studies would help to directly prove our hypothesis that amylin excites AP neurons via formation of cGMP.| |
ACKNOWLEDGEMENTS |
|---|
The expert technical assistance of G. Jurat is greatly appreciated. The authors thank Jan de Vente (University of Maastricht, Maastricht, The Netherlands), who kindly provided the antiserum against cGMP.
| |
FOOTNOTES |
|---|
The studies were supported by Amylin Pharmaceuticals (San Diego, CA).
Address for reprint requests and other correspondence: T. Riediger, Institute of Veterinary Physiology, University of Zurich, Winterthurerstr. 260, 8057 Zurich, Switzerland (E-mail: triedig{at}vetphys.unizh.ch).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 12 March 2001; accepted in final form 27 July 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alm, P,
Skagerberg G,
Nylen A,
Larsson B,
and
Andersson KE.
Nitric oxide synthase and vasopressin in rat circumventricular organs. An immunohistochemical study.
Exp Brain Res
117:
59-66,
1997[Web of Science][Medline].
2.
Arnelo, U,
Reidelberger R,
Adrian TE,
Larsson J,
and
Permert J.
Sufficiency of postprandial plasma levels of islet amyloid polypeptide for suppression of feeding in rats.
Am J Physiol Regulatory Integrative Comp Physiol
275:
R1537-R1542,
1998
3.
Chance, WT,
Balasubramaniam A,
Stallion A,
and
Fischer JE.
Anorexia following the systemic injection of amylin.
Brain Res
607:
185-188,
1993[Web of Science][Medline].
4.
Christopoulos, G,
Perry KJ,
Morfis M,
Tilakarantne N,
Gao Y,
Fraser NJ,
Main MJ,
Foord SM,
and
Sexton PM.
Multiple amylin receptors arise from RAMP interaction with the calcitonin receptor gene product.
Mol Pharmacol
56:
235-242,
1999
5.
Cooper, GJ.
Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease.
Endocr Rev
15:
163-201,
1994
6.
D'Santos, CS,
Gatti A,
Poyner DR,
and
Hanley MR.
Stimulation of adenylate cyclase by amylin in CHO-K1 cells.
Mol Pharmacol
41:
894-899,
1992[Abstract].
7.
De Vente, J,
Hopkins DA,
Markerink-van Ittersum M,
Emson PC,
Schmidt HH,
and
Steinbusch HW.
Distribution of nitric oxide synthase and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain.
Neuroscience
87:
207-241,
1998[Web of Science][Medline].
8.
De Vente, J,
Schipper J,
and
Steinbusch HW.
Formaldehyde fixation of cGMP in distinct cellular pools and their recognition by different cGMP antisera. An immunocytochemical study into the problem of serum specificity.
Histochemistry
91:
401-412,
1989[Web of Science][Medline].
9.
Edwards, GL,
Gedulin BR,
Jodka C,
Dilts RP,
Miller CC,
and
Young A.
Area postrema (AP) lesions block the regulation of gastric emptying by amylin (Abstract).
Gastroenterology
114:
A748,
1998[Web of Science].
10.
Edwards, GL,
Ladenheim EE,
and
Ritter RC.
Dorsomedial hindbrain participation in cholecystokinin-induced satiety.
Am J Physiol Regulatory Integrative Comp Physiol
251:
R971-R977,
1986.
11.
Garbers, DL,
Koesling D,
and
Schultz G.
Guanylyl cyclase receptors.
Mol Biol Cell
5:
1-5,
1994[Web of Science][Medline].
12.
Garthwaite, J,
and
Boulton CL.
Nitric oxide signaling in the central nervous system.
Annu Rev Physiol
57:
683-706,
1995[Web of Science][Medline].
13.
Gedulin, BR,
Rink TJ,
and
Young AA.
Dose-response for glucagonostatic effect of amylin in rats.
Metabolism
46:
67-70,
1997[Web of Science][Medline].
14.
Gross, PM.
Circumventricular organ capillaries.
In: Circumventricular Organs and Brain Fluid Environment, edited by Ermisch A,
Landgraf R,
and Rühle H-J.. Amsterdam: Elsevier, 1992, p. 219-233.
15.
Herman, JP,
Dolgas CM,
Rucker D,
and
Langub MC, Jr.
Localization of natriuretic peptide-activated guanylate cyclase mRNAs in the rat brain.
J Comp Neurol
369:
165-187,
1996[Web of Science][Medline].
16.
Johnson, AK,
and
Gross PM.
Sensory circumventricular organs and brain homeostatic pathways.
FASEB J
7:
678-686,
1993[Abstract].
17.
Jurzak, M,
Schmid HA,
and
Gerstberger R.
NADPH-diaphorase staining and NO synthase immunoreactivity in circumventricular organs of the rat.
In: Integrative and Cellular Aspects of Autonomic Functions: Temperature and Osmoregulation, edited by Pleschka K,
and Gerstberger R.. Paris: Libbey Eurotext, 1994, p. 451-459.
18.
Ladenheim, EE,
and
Ritter RC.
Capsaicin attenuates bombesin-induced suppression of food intake.
Am J Physiol Regulatory Integrative Comp Physiol
260:
R263-R266,
1991
19.
Ladenheim, EE,
and
Ritter RC.
Caudal hindbrain participation in the suppression of feeding by central and peripheral bombesin.
Am J Physiol Regulatory Integrative Comp Physiol
264:
R1229-R1234,
1993
20.
Lutz, TA,
Althaus J,
Rossi R,
and
Scharrer E.
Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers.
Am J Physiol Regulatory Integrative Comp Physiol
274:
R1777-R1782,
1998
21.
Lutz, TA,
Del Prete E,
and
Scharrer E.
Reduction of food intake in rats by intraperitoneal injection of low doses of amylin.
Physiol Behav
55:
891-895,
1994[Medline].
22.
Lutz, TA,
Del Prete E,
and
Scharrer E.
Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin.
Peptides
16:
457-462,
1995[Web of Science][Medline].
23.
Lutz, TA,
Senn M,
Althaus J,
Del Prete E,
Ehrensperger F,
and
Scharrer E.
Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats.
Peptides
19:
309-317,
1998[Web of Science][Medline].
24.
Lutz, TA,
Tschudy S,
Rushing PA,
and
Scharrer E.
Amylin receptors mediate the anorectic action of salmon calcitonin (sCT).
Peptides
21:
233-238,
2000[Web of Science][Medline].
25.
McLatchie, LM,
Fraser NJ,
Main MJ,
Wise A,
Brown J,
Thompson N,
Solari R,
Lee MG,
and
Foord SM.
RAMPs regulate the transport and ligand specificity of the calcitonin receptor-like receptor.
Nature
393:
333-339,
1998[Medline].
26.
Morley, JE,
Flood JF,
Horowitz M,
Morley PM,
and
Walter MJ.
Modulation of food intake by peripherally administered amylin.
Am J Physiol Regulatory Integrative Comp Physiol
267:
R178-R184,
1994
27.
Muff, R,
Buhlmann N,
Fischer JA,
and
Born W.
An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying protein-1 or -3.
Endocrinology
140:
2924-2927,
1999
28.
Murad, F.
Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system.
Adv Pharmacol
26:
19-33,
1994.
29.
Paul, AK,
Marala RB,
Jaiswal RK,
and
Sharma RK.
Coexistence of guanylate cyclase and atrial natriuretic factor receptor in a 180-kD protein.
Science
235:
1224-1226,
1987
30.
Pittner, R,
Beaumont K,
Young A,
and
Rink T.
Dose-dependent elevation of cyclic AMP, activation of glycogen phosphorylase, and release of lactate by amylin in rat skeletal muscle.
Biochim Biophys Acta
1267:
75-82,
1995[Medline].
31.
Pittner, RA,
Albrandt K,
Beaumont K,
Gaeta LS,
Koda JE,
Moore CX,
Rittenhouse J,
and
Rink TJ.
Molecular physiology of amylin.
J Cell Biochem
55 Suppl:
19-28,
1994.
32.
Rauch, M,
Schmid HA,
de Vente J,
and
Simon E.
Electrophysiological and immunocytochemical evidence for a cGMP-mediated inhibition of subfornical organ neurons by nitric oxide.
J Neurosci
17:
363-371,
1997
33.
Reidelberger, RD,
Arnelo U,
Granqvist L,
and
Permert J.
Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats.
Am J Physiol Regulatory Integrative Comp Physiol
280:
R605-R611,
2001
34.
Riediger, T,
Rauch M,
and
Schmid HA.
Actions of amylin on subfornical organ neurons and on drinking behavior in rats.
Am J Physiol Regulatory Integrative Comp Physiol
276:
R514-R521,
1999
35.
Riediger, T,
Schmid HA,
Young AA,
and
Simon E.
Pharmacological characterisation of amylin-related peptides activating subfornical organ neurones.
Brain Res
837:
161-168,
1999[Web of Science][Medline].
36.
Rink, TJ,
Beaumont K,
Koda J,
and
Young A.
Structure and biology of amylin.
Trends Pharmacol Sci
14:
113-118,
1993[Medline].
37.
Ritter, RC,
and
Ladenheim EE.
Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin.
Am J Physiol Regulatory Integrative Comp Physiol
248:
R501-R504,
1985
38.
Rodrigo, J,
Riveros-Moreno V,
Bentura ML,
Uttenthal LO,
Higgs EA,
Fernandez AP,
Polak JM,
Moncada S,
and
Martinez-Murillo R.
Subcellular localization of nitric oxide synthase in the cerebral ventricular system, subfornical organ, area postrema, and blood vessels of the rat brain.
J Comp Neurol
378:
522-534,
1997[Web of Science][Medline].
39.
Rowland, NE,
and
Richmond RM.
Area postrema and the anorectic actions of dexfenfluramine and amylin.
Brain Res
820:
86-91,
1999[Web of Science][Medline].
40.
Schmid, HA.
Nitric oxide acts via cGMP to limit water intake by its inhibitory action on subfornical organ neurons (Abstract).
Amino Acids (Vienna)
13:
57,
1997.
41.
Schmid, HA.
Effect of glutamate and angiotensin II on whole cell currents and release of nitric oxide in the rat subfornical organ.
Amino Acids (Vienna)
14:
113-119,
1998.
42.
Schmid, HA,
and
Pehl U.
Regional specific effects of nitric oxide donors and cGMP on the electrical activity of neurons in the rat spinal cord.
J Chem Neuroanat
10:
197-201,
1996[Web of Science][Medline].
43.
Schmid, HA,
Rauch M,
and
Koch J.
Effect of calcitonin on the activity of ANG II-responsive neurons in the rat subfornical organ.
Am J Physiol Regulatory Integrative Comp Physiol
274:
R1646-R1652,
1998
44.
Schmidt, HHHW,
Lohmann SM,
and
Walter U.
The nitric oxide and cGMP signal transduction system: regulation and mechanism of action.
Biochim Biophys Acta
1178:
153-175,
1993[Medline].
45.
Sexton, PM,
Paxinos G,
Kenney MA,
Wookey PJ,
and
Beaumont K.
In vitro autoradiographic localization of amylin binding sites in rat brain.
Neuroscience
62:
553-567,
1994[Web of Science][Medline].
46.
Shapiro, RE,
and
Miselis RR.
The central neural connections of the area postrema of the rat.
J Comp Neurol
234:
344-364,
1985[Web of Science][Medline].
47.
Silvestre, RA,
Salas M,
Garcia-Hermida O,
Fontela T,
Degano P,
and
Marco J.
Amylin (islet amyloid polypeptide) inhibition of insulin release in the perfused rat pancreas: implication of the adenylate cyclase/cAMP system.
Regul Pept
50:
193-199,
1994[Web of Science][Medline].
48.
Torres, JE,
Kreisman NR,
and
Gozal D.
Nitric oxide modulates in vitro intrinsic optical signal and neural activity in the nucleus tractus solitarius of the rat.
Neurosci Lett
232:
175-178,
1997[Web of Science][Medline].
49.
Van der Kooy, D,
and
Koda LY.
Organization of the projections of a circumventricular organ: the area postrema in the rat.
J Comp Neurol
219:
328-338,
1983[Web of Science][Medline].
50.
Wimalawansa, SJ.
Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily.
Crit Rev Neurobiol
11:
167-239,
1997[Web of Science][Medline].
51.
Young, A.
Role of amylin in nutrient intake
animal studies.
Diabet Med
14 Suppl2:
S14-S18,
1997.
52.
Young, AA,
Gedulin B,
Vine W,
Percy A,
and
Rink TJ.
Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin.
Diabetologia
38:
642-648,
1995[Web of Science][Medline].
This article has been cited by other articles:
![]() |
C. J. Price, T. D. Hoyda, and A. V. Ferguson The Area Postrema: A Brain Monitor and Integrator of Systemic Autonomic State Neuroscientist, April 1, 2008; 14(2): 182 - 194. [Abstract] [PDF] |
||||
![]() |
M. Fry, T. D. Hoyda, and A. V. Ferguson Making Sense of It: Roles of the Sensory Circumventricular Organs in Feeding and Regulation of Energy Homeostasis Experimental Biology and Medicine, January 1, 2007; 232(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Pulman, W. M. Fry, G. T. Cottrell, and A. V. Ferguson The Subfornical Organ: A Central Target for Circulating Feeding Signals J. Neurosci., February 15, 2006; 26(7): 2022 - 2030. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Riediger, D. Zuend, C. Becskei, and T. A. Lutz The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2004; 286(1): R114 - R122. [Abstract] [Full Text] |
||||
![]() |
J. H. Jhamandas, K. H. Harris, C. Cho, W. Fu, and D. MacTavish Human Amylin Actions on Rat Cholinergic Basal Forebrain Neurons: Antagonism of Beta-Amyloid Effects J Neurophysiol, June 1, 2003; 89(6): 2923 - 2930. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Cupples Peptides that regulate food intake Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1370 - R1374. [Full Text] [PDF] |
||||
![]() |
S. Eiden, C. Daniel, A. Steinbrueck, I. Schmidt, and E. Simon Salmon calcitonin - a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents J. Physiol., June 15, 2002; 541(3): 1041 - 1048. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |